Alqassieh Rami, Suleiman Aiman, Abu-Halaweh Sami, Santarisi Abeer, Shatnawi Omar, Shdaifat Lara, Tarifi Amjed, Al-Tamimi Mohammad, Al-Shudifat Abdel-Ellah, Alsmadi Heba, Al Sharqawi Ahmed, Alnawaiseh Hadeel, Anasweh Yara, Domaidah Farah Abo, Jaber Haneen Abu, Al-Zarir Mohammad Rashid, Bsisu Isam
Department of General and Specialized Surgery, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan.
Beth Israel Deaconess Medical Center, Anesthesia and Intensive Care Department, Harvard Medical School, Boston, MA 02215, USA.
Vaccines (Basel). 2021 Oct 21;9(11):1223. doi: 10.3390/vaccines9111223.
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG ( < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects ( < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25-196.15; = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11-0.99; = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
2019冠状病毒病（COVID-19）疫苗通过不同机制诱导免疫。本研究的目的是比较接种辉瑞-生物科技公司COVID-19疫苗或国药集团疫苗的受试者体内特异性抗体的滴度。这项前瞻性观察性队列研究纳入了约旦成年人，他们间隔21天接种了上述两种疫苗中的任意一种的两剂疫苗。在接种第二剂疫苗6周后采集滴度数据。总体而言，共纳入288名参与者，其中141人接种了辉瑞-生物科技公司疫苗，147人接种了国药集团疫苗。值得注意的是，辉瑞-生物科技公司疫苗接种者中有140人（99.3%）IgG滴度呈阳性，而国药集团疫苗接种者中有126人（85.7%）IgG呈阳性（P<0.001）。辉瑞-生物科技公司疫苗接种者中IgG的平均滴度为515.5±1143.5 BAU/mL，而国药集团疫苗接种者中为170.0±230.0 BAU/mL（P<0.001）。多变量回归分析显示，与心血管疾病对IgG滴度的负面影响（比值比：0.33；95%置信区间：0.11-0.99；P=0.048）相比，辉瑞-生物科技公司疫苗与阳性IgG滴度呈正相关（比值比：25.25；95%置信区间：3.25-196.15；P=0.002）。总之，与国药集团疫苗接种者相比，完全接种辉瑞-生物科技公司疫苗的接种者具有更高的定量效率。支持国药集团疫苗接种者或患有慢性免疫抑制疾病的人接种加强针。
